Optimization of Methionyl tRNA-Synthetase Inhibitors for Treatment of Cryptosporidium Infection

Area of Science:

• Medicinal Chemistry
• Parasitology
• Drug Discovery

Background:

• Cryptosporidiosis is a significant cause of diarrhea in children, particularly in resource-limited settings.
• Current treatment options, like nitazoxanide, are ineffective in key populations such as malnourished children and HIV-infected individuals.
• The limited therapeutic landscape necessitates the development of novel anticryptosporidial agents.

Purpose of the Study:

• To discover and optimize novel imidazopyridine-containing compounds for treating Cryptosporidium infections.
• To investigate the mechanism of action and in vivo efficacy of these compounds.
• To identify key pharmacological and physicochemical properties associated with therapeutic efficacy.

Main Methods:

• Discovery and optimization of imidazopyridine derivatives targeting Cryptosporidium methionyl-tRNA synthetase (MetRS).
• Biochemical assays to determine enzyme inhibition constants (Ki).
• In vitro cell culture assays to assess anti-Cryptosporidium activity and selectivity.
• Parasite persistence and murine models of cryptosporidiosis to evaluate in vivo efficacy and toxicity.

Main Results:

• Identified potent MetRS inhibitors with Ki values in the low picomolar range.
• Achieved high in vitro efficacy against Cryptosporidium with 50% effective concentrations as low as 7 nM.
• Demonstrated >1,000-fold selectivity for parasite over mammalian cells.
• Compounds exhibited parasiticidal activity and controlled infection in murine models without observed toxicity.

Conclusions:

• Imidazopyridine-based MetRS inhibitors represent a promising new class of therapeutics for cryptosporidiosis.
• These compounds display potent activity, high selectivity, and favorable in vivo efficacy.
• Further development of MetRS inhibitors is warranted for anticryptosporidiosis therapy.